5.17
+0.4(+8.39%)
Currency In USD
| Previous Close | 4.77 |
| Open | 4.8 |
| Day High | 6.03 |
| Day Low | 4.8 |
| 52-Week High | 22.06 |
| 52-Week Low | 4.1 |
| Volume | 173,857 |
| Average Volume | 52,110 |
| Market Cap | 7.89M |
| PE | -0.14 |
| EPS | -37.05 |
| Moving Average 50 Days | 8.49 |
| Moving Average 200 Days | 9.7 |
| Change | 0.4 |
If you invested $1000 in BiomX Inc. (PHGE) since IPO date, it would be worth $2.82 as of December 07, 2025 at a share price of $5.17. Whereas If you bought $1000 worth of BiomX Inc. (PHGE) shares 5 years ago, it would be worth $4.44 as of December 07, 2025 at a share price of $5.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
GlobeNewswire Inc.
Nov 25, 2025 9:40 PM GMT
The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trial An independent Data Monitorin
BiomX Inc. Announces 1-for-19 Reverse Stock Split
GlobeNewswire Inc.
Nov 14, 2025 9:31 PM GMT
NESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announc
BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025
GlobeNewswire Inc.
Nov 05, 2025 1:30 PM GMT
NESS ZIONA, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today annou